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OOThe family of human papillomaviruses (HPVs) includes more than 130 genotypes, many of which infect thegenital tract, and these can be classified as low risk or high risk for induction of genital neoplasia. Twoprophylactic vaccines are currently available for the prevention of genital HPV infection: a quadrivalent
(Gardasil®; Merck & Co. Inc) and a bivalent (Cervarix™; GlaxoSmithKline) vaccine. Protection against HPV
infection and associated disease is observed for at least 6.4 years following immunization with the bivalent
vaccine and for at least 8.5 years with the HPV 16 L1 virus-like particle of the quadrivalent vaccine. HPV
vaccines induce robust immune memory, as evidenced by recall of responses after revaccination, suggesting
that immunization will afford long-lasting protection. An immunological marker for ongoing protection from
infection would provide information to help establish best-practice deployment of these vaccines. However,
while HPV-specific antibody is likely the major mechanism of protection against HPV infection following
immunization, available serological assays provide only a partial characterization of immune status, and no
measured immune response has been shown to define immediate or future protection against HPV infection
or associated disease. Future research efforts should therefore be directed towards correlating measures of
virus-specific immune memory with continued protection against infection with the HPV types in the
available vaccines, and towards determining the duration of cross-protection afforded by these vaccines
against HPV types other than those incorporated in the vaccines.35
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Human papillomaviruses (HPVs) constitute a large family of
viruses, with over 130 genotypes. The more than 30 genotypes that
62
63
64infect the genital tract can be classified into either low-risk types that
cause genital warts, such as HPV 6 or 11, or high-risk types that
promote the development of cervical cancer, such as HPV 16 and 18
[1,2]. Characterization of the immune responses to the structural and
non-structural proteins of HPVs is necessary to understand how prior
infection or immunization might protect against future infection and




































































































































Papillomaviruses are non-enveloped viruses that have an 8-kb
circular genome enclosed in a protein capsid [3]. The capsid comprises
virally encoded major (L1) and minor (L2) structural proteins, both of
which are synthesized late in the infectious cycle [4]. Pentamers of L1
form an icosahedral capsid shell comprised of 72 L1 pentamers, and
approximately 12molecules of L2, which are largely located inside the
L1 capsid [5]. L1 sequences are highly conserved between HPV
genotypes, though peptide segments, variable between genotypes,
are interspersed among segments of conserved regions. The crystal
structure of the virus suggests that the variable regions are primarily
displayed on the outer surface of the capsid [4]. The majority of
measured immune responses to HPV virions elicited by natural
infection or vaccination appear to be directed to the variable regions
of the L1 protein. Under appropriate conditions in vitro, HPV L1 capsid
protein self-assembles into non-infectious virus-like particles (VLPs)
which resemble the native virus immunologically [4], making them
ideal components for HPV vaccines.
The HPV L1 VLP vaccines
Two prophylactic HPV vaccines are currently licensed: a quadriva-
lent (Gardasil®; Merck and Co. Inc) and a bivalent (Cervarix™;
GlaxoSmithKline) vaccine. The quadrivalent vaccine is administered
intramuscularly as 3 separate 0.5 mL doses; the second dose is admin-
istered 2 months after the first dose and the third dose 4 months later
[3]. Each dose of vaccine consists of HPV 6, 11, 16, and 18 L1 VLPs plus
the proprietary adjuvant amorphous aluminum hydroxysulfate [1]. The
bivalent vaccine consists of HPV 16 and 18 L1 VLPs plus the adjuvant
system AS04, comprised of aluminum hydroxide and monophosphoryl
lipid A, a modified endotoxin and agonist of toll-like receptor 4 [1]. It is
administered according to a 3-dose protocol at 0, 1, and 6 months.
Both vaccines provide durable protection against infection with
the incorporated HPV types and associated disease, that has been
observed up to 6.4 years for the bivalent vaccine [6–8] and up to
8.5 years for the HPV 16 L1 VLP of the quadrivalent vaccine [9–12].
The bivalent vaccine has demonstrated protective efficacy against
cervical intraepithelial neoplasia (CIN) associated with HPV 16 and 18
when administered according to a 3-dose immunization schedule in
women aged 15–25 years [6,8,13]. The quadrivalent vaccine has
demonstrated protective efficacy against CIN and other anogenital
preneoplastic conditions related to HPV 16 and 18 in women, and to
genital warts associated with HPV 6 and 11 in women and men aged
15–26 years [9,10,14–16].
Immune response after immunization
The goal of immunization is to prevent disease following first
exposure to a target pathogen in a previously uninfected subject. This is
achieved by induction of a primary immune response which not only
reduces the immediate infectivity of any pathogen challenge, but also
enables a swift secondary immune response to the pathogen following
such challenge, which can limit the capacity of the pathogen to induce
disease. Following a single immunization, a primary immune response
is measurable as low affinity immunoglobulin M (IgM) antibody after a
period of 4–8 days [17]. This antibody response reaches a plateau
between12 and 18 days after immunization and then declines.
Following a second exposure to the same antigen through immuniza-
tion or challenge, a further antibody response occurs, characterized by a
shorter time to induction and a markedly higher level of antibody: this
secondary or memory response typically also comprises antibody of a
different class (immunoglobulin G [IgG]) and higher affinity for the
antigen [17].
The currently available VLP-based HPV vaccines present confor-
mational epitopes found on the natural HPV virus and prime the
immune system to generate antibodies which can neutralize the virus






VLPs are highly immunogenic. HPV immunization induces peak
geometric mean antibody titers that are 80- to 100-fold higher than
those observed following natural infection [19]. Furthermore, after
18 months, mean vaccine-induced antibody titers remain 10- to 16-
fold higher than those recorded with natural infection [19], and these
levels appear to be preserved over time, suggesting that immuniza-
tion may provide long-term protection against infection. Neutralizing
antibody to papillomavirus is sufficient to prevent infection following
challenge with virus in animal models, though persistence of mea-
surable antibody may not be necessary to prevent disease following
exposure in humans.
Anti-HPV antibody measurements
Measurable immune responses to viral proteins in humans
following proven HPV infection are weak and inconsistent, and the
mechanism and extent of any immune protection against reinfection
with HPV following natural infection is unknown, though primary
infection in cattle and dogs with their papillomaviruses prevents
disease following subsequent challenge. Following immunization
with HPV, measurable immune responses to the viral capsid are
consistently observed. However, no immune responses have been
defined that correlate with protection against infection or disease
following subsequent natural exposure to HPV [1]. A surrogatemarker
for protection against HPV infection or disease following exposure to
HPV in previously immunized or naturally infected individuals would
assist in developing effective immunization protocols, define any
requirement for booster immunization, and determine the utility of
any cross-protection induced to HPV types not in the current vaccines
[14]. Such a marker would also facilitate introduction of new HPV
types into future HPV vaccines.
Definition of an appropriate HPV serological assay to monitor the
response to natural infection and immunization is particularly chal-
lenging given that a portion of naturally infected and of vaccinated
individuals do not become seropositive to any currently available
assay, and yet are apparently protected against disease following
further infection [18]. An evaluation of the correlation between
quadrivalent vaccine-induced serum anti-HPV responses and efficacy
in 17,622 women could discern no correlation between antibody
levels and HPV infection or disease due to the low number of disease
cases. After up to 48 months of follow-up, overall vaccine efficacy was
98.4%. Though 40% of vaccine recipients lacked measurable antibody
to HPV 18 at 48 months, there were no cases of HPV 18 infection or
related disease in vaccine recipients, but there were 26 cases in the
unimmunized control group. These findings indicate that the
protection conferred by immunization occurs with HPV 18 antibody
titers that are below detectable limits [14]. This protection could
either be due to recall by infection of a protective memory B-cell
response, to failure of current antibody assays to detect the
appropriate antibody type or specificity, or to a non-antibody-
dependent mechanism of immune protection involving T-cell
memory.
The pivotal clinical trials evaluating the two currently licensed
vaccines have used different methods to evaluate virus-specific IgG
antibody titers after immunization, and therefore serological data
are not directly comparable between the studies. The quadrivalent
vaccine trials used a competitive Luminex® assay (cLIA) or a com-
petitive radioimmunoassay (cRIA), which uses multiplex technology
to detect defined type- and epitope-specific antibodies against HPV 6,
11, 16, and 18 VLPs [18,20]. The different binding affinity of each
monoclonal antibody for its epitope on the VLP, and the different
proportion of the available epitopes represented by the antibodies
used for different HPV types, preclude valid comparisons of mag-
nitude of measured immune response to different HPV types for these
assays. The bivalent vaccine trials used an enzyme-linked immuno-































































































































measures total serum anti-VLP IgG antibody to all epitopes presented
by the VLPs. It does not discriminate between type-specific confor-
mational antibodies and type-common antibodies, which tend to be
specific for epitopes presented by denatured L1 and which are rarely
neutralizing [20]. None of the essays examines antibody affinity or
avidity, nor determines the in vivo neutralization potential of serum,
though the cLIA and cRIA assays can be designed to be specific for
antibodies recognizing some of the virus epitopes that bind known
neutralizing antibody. None of the essays distinguishes vaccine-
induced antibody to one HPV type from antibody raised against other
HPV types by vaccination or natural infection [20]. Thus, without a
demonstrated correlate of immune response in either assay with
clinical protection, none of the essays can be said to be useful for
measuring the effectiveness of vaccination. However, each assay can
be used to provide data on relative immunogenicity of the same
vaccine product in different patient populations, which is important
for bridging studies designed to validate the use of immunization in
populations (e.g. children prior to onset of sexual activity) that,
because of the low incidence of disease, are not amenable to
conventional clinical efficacy studies.
Type specificity of neutralizing antibodies
Immunization with VLPs can protect individuals from subsequent
exposure to infection. Protection against papillomavirus infection can
also occur via passive transfer of serum antibodies between
vaccinated or naturally infected animals and naive animals, demon-
strating that specific antibodies are sufficient to give protection.
Immunization with HPV VLPs predominantly produces type-specific
virus neutralizing antibodies, though some cross-protection against
other related HPV types is observed, both in preclinical studies and in
clinical trials [1,5,21]. In particular, cross-reactivity has been observed
between HPV 16, 31, 33, and 58 and between HPV 18 and 45 [1],
indicating that immunization with one HPV type may offer some
degree of cross-protection against others [1]. However, cross-
neutralization elicited by L1 VLPs represented b1% of the neutralizing
activity induced by the dominant conformational epitopes, and the
affinity and duration of such cross-neutralizing antibody is currently
unknown.
Immune memory
Following natural HPV infection, serum antibody levels to HPV 16
remain stable overmore than 4 years of follow-up [22]. Serum antibody
levels are routinely used to monitor vaccine efficacy. However,
following immunization, there are few data on the regulation and
maintenance of antibody levels over long periods of time in the absence
of constant antigenic stimulation [23].
Humoral immune responses to infection or immunization are
characterized by an initial IgM response, and subsequent production
of IgG of increasing affinity for the relevant antigen, due to selection of
higher avidity B-cell clones following somatic hypermutation of
antibody genes. Antibody production is largely by plasma cells located
in lymph node germinal centers and in mucosal tissues at sites of
inflammation. The majority of these cells have a limited lifespan, but
some persist, ensuring ongoing production of low levels of antibody
over the lifetime of the animal. In addition, an expanded population
of antigen-specific memory B and T cells are produced following
immunization that can more rapidly respond to antigen following a
further exposure to the same initial pathogen [23,24]. Immune mem-
ory is the basis for long-term protection against disease following
immunization: high-affinity B-cell memory develops under the
guidance of helper T cells [1]. Following further antigen exposure,
these antigen-specific B and T cells undergo extensive proliferation,
rapidly producing high-affinity antibody to prevent spread of the






Following infection or immunization, peak serum antibody levels
are reached within a month, decline over subsequent months, and are
then maintained at constant levels for long periods of time [23].
Smallpox vaccine-specific memory B cells can be detected≥60 years
after immunization; significantly, antibody levels have been shown
to have remained stable between 10 and 60 years after pathogen
exposure [25]. However, the exact mechanism by which serum
antibody levels are maintained over a long period of time in the
absence of antigenic stimulation remains to be determined [23].
Preclinical evidence indicates that several distinct mechanisms may
contribute to sustained antibody levels, including the longevity of a
subset of antigen-specific plasma cells, continuous antigenic stimu-
lation of memory B cells by small amounts of antigen persisting in
specialized antigen-presenting cells in the lymph node [23], and slow
homeostatic activation of all memory B cells without antigen
exposure, leading to ongoing low level production of antibody [23].
Further research is necessary to determine whether different vaccines
elicit different memory responses.
A study in 552 women aged 16–23 years indicates that the quad-
rivalent HPV vaccine induces robust immune memory [26]. Following
a 3-dose regimen, serum anti-HPV levels declined postimmuniza-
tion, reaching a plateau at 24 months. In a subset of women followed
for 60 months, serum anti-HPV levels remained stable; 1 week and
1 month after administration of a challenge dose of quadrivalent
vaccine, anti-HPV levels remained higher than those observed
following the initial immunization series [26].
Future perspectives
The best evidence of induction of effective long-term immunity
following immunization is ongoing protection against disease.
Current data report promising results regarding the durability of
HPV vaccine-induced protection, with ongoing efficacy demonstrated
over periods of up to 8.5 years. HPV vaccines induce robust memory
immune responses which should ensure long-lasting protection. Future
research efforts should therefore be directed towards correlating
measures of virus-specific immune memory with continued protection
against infection with the HPV types in the available vaccines, and
towards determining the duration of cross-protection afforded by these
vaccines against HPV types other than those incorporated in the
vaccines.
Key points
• HPV vaccines induce virus-specific antibody, sufficient to protect
against HPV-associated disease, though antibody may not be the
sole mechanism of protection.
• Antibody to conformational epitopes on the viral capsid is more
effective for virus neutralization than antibody to linear or
denatured capsid protein.
• Humoral immune responses to HPVmeasured by currently available
assays do not predict individual protection against disease.
• Following vaccination, immunememory is an important component
of ongoing protection.
• HPV vaccination induces some cross-protective immunity against
other HPV types, but the significance for long-term protection of
cross-reactive antibody is unknown.
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